

Resource Summary Report

Generated by [RRID](#) on Sep 7, 2026

Anti-Rad51 antibody

RRID:AB_2722613

Type: Antibody

Proper Citation

Abcam Cat# ab133534, RRID:AB_2722613

Antibody Information

URL: http://antibodyregistry.org/AB_2722613

Proper Citation: Abcam Cat# ab133534, RRID:AB_2722613

Target Antigen: Rad51

Host Organism: rabbit

Clonality: monoclonal

Comments: Suitable for: WB, IHC-P, ICC/IF, Flow Cyt, IP

Antibody Name: Anti-Rad51 antibody

Description: This monoclonal targets Rad51

Target Organism: rat, mouse, human

Clone ID: EPR4030(3)

Antibody ID: AB_2722613

Vendor: Abcam

Catalog Number: ab133534

Record Creation Time: 20231110T033720+0000

Record Last Update: 20260831T203947+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Rad51 antibody.

No alerts have been found for Anti-Rad51 antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 59 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Uboveja A, et al. (2026) ??KG-mediated carnitine synthesis drives DNA repair via histone acetylation. *Nature*, 655(8123), 790.

Llop-Guevara A, et al. (2026) RAD51-based homologous recombination deficiency is associated with treatment response and survival in early breast cancer. *NPJ breast cancer*, 12(1).

Chatterjee S, et al. (2026) Pathogenesis of Noonan Syndrome is Modulated by NOC2L, a Novel Interactor of LZTR1 Leading to Impaired P53 Signalling. *The Journal of clinical endocrinology and metabolism*, 111(5), 1418.

Xu G, et al. (2026) Delactylation of the tumor suppressor ARHGDIB drives metastasis and chemoresistance in bladder cancer. *Cell reports*, 45(2), 116941.

Liu Y, et al. (2026) C1QBP-STAT1 Interaction Promotes Activation of the c-Myc-CHK1/CHK2 Signaling Axis and Radioresistance in Lung Cancer. *Molecular cancer research : MCR*, 24(5), 315.

Criscuolo D, et al. (2026) KRAS-mediated CCDC6 degradation drives xCT upregulation and ferroptosis evasion. *Apoptosis : an international journal on programmed cell death*, 31(8).

Meng H, et al. (2026) Multiomics profiling and experiments in preclinical models revealed RAD51-IN-1 as a synergistic potentiator of anlotinib sensitivity. *Science advances*, 12(16), eaeb0855.

Adeyanju O, et al. (2026) Prenatal and postnatal atrazine-induced endocrine and ovarian chemical biotransformation protein disruption in offspring. *Journal of the Endocrine Society*, 10(3), bvag027.

Gu JJ, et al. (2026) ABL kinase inactivation induces transcription-replication conflicts and impairs replication fork progression in metastatic small cell lung cancer. *Cell reports*, 45(7), 117699.

Zhang J, et al. (2026) RNA exonuclease REXO4 resolves m6A-marked R-loops and suppresses anti-tumor immunity. *Molecular cell*.

Criscuolo D, et al. (2026) CCDC6 Immunostaining in Conjunction with the Rad51 HRD Assay May Expand PARPi Treatment Eligibility in Patients with HGSOC. *Cancer research communications*, 6(1), 201.

Sun S, et al. (2026) CBX2 phase-separation contributes to homologous recombination repair and drug resistance in ovarian cancer. *Cell death & disease*, 17(1).

Monferini N, et al. (2026) Transcriptome profiling of bovine preantral follicles during early folliculogenesis. *Journal of animal science and biotechnology*, 17(1).

Wang Y, et al. (2025) PALB2 and 53BP1 govern post-resection homologous recombination DNA repair. *Molecular cell*, 85(15), 2824.

Giuntini F, et al. (2025) MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. *Cell reports*, 44(12), 116604.

Alruwaili MM, et al. (2025) A Sequential Triple-Drug Strategy for Selective Targeting of p53-Mutant Cancers. *bioRxiv : the preprint server for biology*.

Luna-Maldonado F, et al. (2025) Protocol for induction and study of DNA double-strand breaks in mammalian cells using PALM microdissection and expansion microscopy. *STAR protocols*, 6(3), 103938.

Lu YF, et al. (2025) WDFY2 promotes MRN complex formation required for homologous recombination-mediated DNA repair. *Cell reports*, 44(11), 116520.

Arce-Gallego S, et al. (2025) Homologous recombination repair status in metastatic prostate cancer by next-generation sequencing and functional immunofluorescence. *Cell reports. Medicine*, 6(2), 101937.

Devanathan SK, et al. (2025) MePCE promotes homologous recombination through coordinating R-loop resolution at DNA double-stranded breaks. *Cell reports*, 44(6), 115740.